Skip to main content
Kasra Karamlou, MD, Oncology, Avon, OH, Cleveland Clinic

KasraKaramlouMD

Oncology Avon, OH

Physician

Dr. Karamlou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Karamlou's full profile

Already have an account?

  • Office

    Cleveland Clinic - Avon Hospital at Richard E. Jacobs Campus
    33100 Cleveland Clinic Blvd
    Avon, OH 44011
    Phone+1 419-626-9090
    Fax+1 480-854-6769
  • Is this information wrong?

Education & Training

  • Oregon Health & Science University
    Oregon Health & Science UniversityFellowship, Hematology and Medical Oncology, 1999 - 2003
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 1996 - 1999
  • George Washington University School of Medicine and Health Sciences
    George Washington University School of Medicine and Health SciencesClass of 1996

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2000 - Present
  • OH State Medical License
    OH State Medical License 2018 - 2025
  • CA State Medical License
    CA State Medical License 2012 - 2022
  • AZ State Medical License
    AZ State Medical License 2016 - 2019
  • WA State Medical License
    WA State Medical License 2005 - 2013
  • TX State Medical License
    TX State Medical License 1998 - 2000
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2014

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Phase 2 Study of Duvelisib in Previously Treated Patients with Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (BRIO)
    Phase 2 Study of Duvelisib in Previously Treated Patients with Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (BRIO)December 12th, 2017

Professional Memberships

Other Languages

  • Farsi

Hospital Affiliations